Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134546 | 0.76 | CA2 (0.41) | TP53CA2CA1CA12CA7 | |
| SCHEMBL27289489 | 0.75 | TP53 (0.37) | TP53DNM1TSHRSMN1; SMN2FDPS | |
| SCHEMBL5888772 | 0.75 | TP53 (0.37) | TP53DNM1TSHRSMN1; SMN2FDPS | |
| SCHEMBL28313790 | 0.73 | CA2 (0.36) | TP53DNM1TSHRSMN1; SMN2FDPS | |
| SCHEMBL6113068 | 0.73 | TP53 (0.45) | TP53DNM1TSHRSMN1; SMN2FDPS | |
| SCHEMBL14892962 | 0.71 | TP53 (0.43) | TP53DNM1FDPSCA2CA1 | |
| SCHEMBL20084326 | 0.71 | TSHR (0.38) | TP53DNM1TSHRSMN1; SMN2FDPS | |
| SCHEMBL1415215 | 0.71 | TP53 (0.34) | TP53DNM1TSHRSMN1; SMN2FDPS | |
| SCHEMBL17213651 | 0.71 | CA2 (0.34) | TP53DNM1TSHRSMN1; SMN2FDPS | |
| SCHEMBL27516526 | 0.70 | TP53 (0.41) | TP53DNM1TSHRSMN1; SMN2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010018113-A2 | BI-ARYL AMINOTETRALINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | BLANC JEAN-BAPTISTE | 2010-02-18 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | HRH4, HRH2, HRH1 | TP53 4541/4885DNM1 4749/4885TSHR 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.